RxDoctor Payments DataLook up a doctor →

Anthony Hunter, MD

Hematology & Oncology · Atlanta, GANPI 1053731612

Payments from drug & device makers

$4,260,594in general payments, 2019–2025

Across 1,148 payments — averaging $3711.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2.5M
  • Incyte Corporation$1.4M
  • Pharmaessentia USA Corporation$190K
  • Sumitomo Pharma America, Inc.$68K
  • Blueprint Medicines Corporation$34K
  • Geron Corporation$3K
  • plus $5K from 11 others
$470in research payments, 2019–2025

Across 2 payments — averaging $234.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$470

What the payments were for

  • Consulting fees$16,96867%
  • Speaking & faculty fees$5,78923%
  • Travel & lodging$7453%
  • Food & beverage$1,5976%
  • Education$1781%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,260,594 in reported general payments places this provider in the 95th percentile of 370 hematology & oncology providers in Georgia.

See all hematology & oncology providers in Georgia

Medicare billing

Part B allowed, 2024
$27,520
Medicare patients
142
Services billed
359

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate188$2,979,752
AyvakitAvapritinib51$1,991,271
BesremiRopeginterferon Alfa-2b-Njft88$1,258,129
OjjaaraMomelotinib Dihydrochloride29$809,447
VonjoPacritinib Citrate33$745,877
ScemblixAsciminib Hydrochloride19$381,782
BosulifBosutinib14$248,645
SprycelDasatinib11$178,893
VenclextaVenetoclax20$167,213
PegasysPeginterferon Alfa-2a35$161,962
EliquisApixaban19$15,630
XareltoRivaroxaban11$8,608
Hydroxyurea123$3,355
Prochlorperazine Maleate24$220
Allopurinol13$166

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$1,446,698$2,979,752188 claims
Blueprint Medicines CorporationAyvakit$33,523$1,991,27151 claims
Pharmaessentia USA CorporationBesremi$189,661$1,258,12988 claims
GSKOjjaara$1,160$809,44729 claims
NovartisScemblix$2,515,984$381,78219 claims
AbbVieVenclexta$122$167,21320 claims
Johnson & JohnsonXarelto$20$8,60811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 370 hematology & oncology providers in Georgia.

Other hematology & oncology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →